Two additional Phase 3 oral assets are particularly useful to watch because they represent next entrants rather than franchise conversions: HDM1002 (conveglipron) HDM1002 is being positioned publicly as a selective oral small-molecule GLP-1R agonist for type 2 diabetes and obesity
Provincial/Regional Health Authorities and Hospitals Send out a provincial, regional, or hospital alert to all staff, including anesthesia teams, about the increased risk of aspiration for patients who are taking GLP-1 receptor agonists, especially when used for weight loss
You and your family can connect with board-certified doctors anytime, day or night, through secure phone or video calls
This innovative technique has revealed that the solid stress imposed on murine breast tumors is ~ 2 kPa, a magnitude 5 to 8 times higher than the stress that individual cancer cells sense within the primary tumor [116]
Zepbound is the only one that's FDA-approved for sleep apnea, specifically among people with obesity (defined as a BMI of over 30)
Employer coverage trends The employer landscape told a more nuanced story
.png?width=1000&height=500&name=microneedle%20types%20diagram%20(1).png)
